C-Cure Clinical Trial

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 16% of the time (370 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellheartventricularfailureleft
  Phrases that lowered it: clinical trialsubject hasbody massmass indexbmi
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 2/3 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. NCT01768702 · started 2012 · scored riskier than 89% of active trials completed
• Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure NCT02501811 · started 2015 · scored riskier than 69% of active trials completed
• Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy NCT01020968 · started 2009 · scored riskier than 99% of active trials completed
• A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure NCT02467387 · started 2014 · scored riskier than 81% of active trials completed
• Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. NCT02033278 · started 2014 · scored riskier than 79% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.